Wall Street Zen Downgrades MBX Biosciences (NASDAQ:MBX) to Sell

Key Points

• MBX Biosciences has been downgraded from a "hold" rating to a "sell" rating by analysts at Wall Street Zen.
• The company's stock opened at $11.55, with a market cap of $387.96 million and a P/E ratio of -2.54.
• MBX Biosciences specializes in developing novel precision peptide therapies for endocrine and metabolic disorders.

MBX Biosciences (NASDAQ:MBX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

MBX Biosciences Price Performance

Shares of MBX Biosciences stock traded down $0.33 during midday trading on Friday, hitting $9.93. 330,107 shares of the company were exchanged, compared to its average volume of 310,256. The company has a market capitalization of $333.59 million and a PE ratio of -2.19. MBX Biosciences has a 52 week low of $4.81 and a 52 week high of $27.50.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.